Compass Therapeutics (CMPX) Other financing activities (2020 - 2026)
Compass Therapeutics recorded quarterly Other financing activities of -$489000.0 in Q1 2026, down 105.66% quarter-over-quarter from $8.6 million in Q3 2025, and up 40.0% year-over-year from -$349285.7 in Q1 2025.
Compass Therapeutics' Other financing activities history runs 6 years deep, the most recent figure standing at -$489000.0 for Q1 2026.
- In Q1 2026, Other financing activities rose 40.0% year-over-year to -$489000.0; the TTM figure through Mar 2026 stood at $9.0 million (up 6691.18% YoY), while the FY2025 annual figure was $8.6 million, up 1490.79% from the prior year.
- Other financing activities came in at -$489000.0 for Q1 2026 at Compass Therapeutics, down from $8.6 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $8.6 million in Q3 2025 to a low of -$815000.0 in Q1 2025.
- A 4-year average of $937555.6 and a median of -$2000.0 in 2024 frame the typical range for Other financing activities.
- On a YoY basis, Other financing activities climbed as much as 431800.0% in 2025 and fell as far as 499.26% in 2025.
- Compass Therapeutics' Other financing activities stood at -$254000.0 in 2023, then jumped by 99.21% to -$2000.0 in 2024, then surged by 432000.0% to $8.6 million in 2025, then sank by 105.66% to -$489000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered -$489000.0, $8.6 million, and $815000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -489,000.00 |
| Mar 31, 2026 | -489,000.00 |
| Sep 30, 2025 | 8.64 Mn |
| Sep 30, 2025 | 8.64 Mn |
| Jun 30, 2025 | 815,000.00 |
| Jun 30, 2025 | 815,000.00 |
| Mar 31, 2025 | -815,000.00 |
| Mar 31, 2025 | -815,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 679,000.00 |
| Jun 30, 2024 | 679,000.00 |
| Mar 31, 2024 | -136,000.00 |
| Mar 31, 2024 | -136,000.00 |
| Dec 31, 2023 | -254,000.00 |
| Dec 31, 2023 | -254,000.00 |
| Dec 31, 2021 | 281,000.00 |
| Dec 31, 2021 | 281,000.00 |
| Sep 30, 2020 | 6.32 Mn |
| Sep 30, 2020 | 6.32 Mn |
| Jun 30, 2020 | 5.52 Mn |
| Jun 30, 2020 | 5.52 Mn |